(Total Views: 605)
Posted On: 11/08/2020 1:21:05 PM
Post# of 72446
Brilacidin COVID-19 Preprint Now on BioRxiv.org
Dear Shareholders,
We are pleased to inform shareholders that the Brilacidin preprint article based on in vitro anti-SARS-CoV-2 research conducted at George Mason University’s National Center for Biodefense and Infectious Diseases can now be viewed in its entirety on BioRxiv.org at the link below. The paper strongly supports Brilacidin’s COVID-19 treatment potential.
https://www.biorxiv.org/content/10.1101/2020....450v1.full
Dear Shareholders,
We are pleased to inform shareholders that the Brilacidin preprint article based on in vitro anti-SARS-CoV-2 research conducted at George Mason University’s National Center for Biodefense and Infectious Diseases can now be viewed in its entirety on BioRxiv.org at the link below. The paper strongly supports Brilacidin’s COVID-19 treatment potential.
https://www.biorxiv.org/content/10.1101/2020....450v1.full
(12)
(1)
